Gene Rearrangements in Soft Tissue Tumors

Gene rearrangements are a principal mechanism driving the development and diversity of soft tissue tumours. Chromosomal translocations can fuse coding sequences from two distinct genes, giving rise to novel fusion proteins with oncogenic potential. Such events underpin the pathogenesis of a broad spectrum of malignancies—ranging from highly aggressive sarcomas, exemplified by EWSR1–FLI1 in Ewing sarcoma and SS18–SSX in synovial sarcoma, to low-grade neoplasms and reactive pseudotumours, such as those harbouring USP6 rearrangements. The identification of recurrent fusion genes has transformed diagnosis: molecular assays now complement histopathology to deliver precise subclassification, prognostic stratification and tailored therapeutic decisions. In recent years, comprehensive genomic profiling and single-cell analyses have revealed that gene-fusion landscapes vary not only between distinct tumour types but also within individual lesions, highlighting intratumoural heterogeneity. Importantly, certain fusion products represent therapeutic vulnerabilities, as evidenced by the clinical success of TRK inhibitors in NTRK-rearranged sarcomas. Global efforts continue to map the full repertoire of gene rearrangements, elucidate their biochemical mechanisms and develop innovative diagnostic platforms. The convergence of genomic technology, bioinformatics and targeted drug development promises to refine patient management, reduce treatment toxicity and improve long-term outcomes for individuals affected by soft tissue tumours worldwide.

Research from Nature Portfolio

Recent studies have exploited high-resolution genome sequencing to catalogue fusion events across diverse soft tissue sarcomas. One investigation employed single-cell transcriptomics to dissect intratumoural heterogeneity in fusion-positive sarcomas, revealing subpopulations that differentially express driver fusion transcripts and signalling pathways linked to cell invasiveness. A separate study used long-read sequencing to characterise previously cryptic rearrangements in paediatric sarcomas, uncovering novel fusion partners that escape detection by routine assays. Together, these advances have sharpened our understanding of fusion-driven oncogenesis and have informed the design of more sensitive molecular diagnostics, particularly for atypical or translocation-negative cases.

Gene Rearrangements in Soft Tissue Tumors publication trend

The graph below shows the total number of articles in gene rearrangements in soft tissue tumors across all publications each year (not limited to Nature Index journals).

Technical terms

Chromosomal translocation: A structural rearrangement in which segments from two chromosomes exchange places, often generating fusion genes.

Fusion gene: A hybrid gene created by joining parts of two separate genes, frequently encoding an oncogenic protein.

Soft tissue tumour: A neoplasm arising from mesenchymal tissues such as muscle, fat, fibrous tissue or blood vessels.

USP6 rearrangement: A specific gene fusion involving the ubiquitin-specific peptidase 6 (USP6) gene, characteristic of certain benign lesions and pseudotumours.

Single-cell transcriptomics: A technique that profiles gene expression in individual cells, revealing heterogeneity within a tumour.

Long-read sequencing: A genomic method that produces extended DNA sequence reads, improving detection of complex rearrangements.

References

1. Myositis ossificans – Another condition with USP6 rearrangement, providing evidence of a relationship with nodular fasciitis and aneurysmal bone cyst. Annals of Diagnostic Pathology (2018).
2. Nodular fasciitis: a comprehensive, time-correlated investigation of 17 cases. Modern Pathology (2021).
3. USP6-associated soft tissue tumors with bone metaplasia: Clinicopathologic and genetic analysis and the identification of novel USP6 fusion partners. Frontiers in Oncology (2023).